publication venue for
- Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers. 49:997-1004. 2019
- Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to dietary restriction. 50:517-529. 2019
- Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. 49:1223-1229. 2019
- Randomised clinical trial: gluten may cause depression in subjects with non-coeliac gluten sensitivity - an exploratory clinical study. 39:1104-1112. 2014
- Letter: the gluten-free diet as a bottom-up approach for irritable bowel syndrome. Authors' reply 2020
- Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs 2016
- Editorial: noncoeliac gluten sensitivity - a disease of the mind or gut? Authors' reply 2014
- Editorial: effects of vildagliptin on GLP-1 levels, gastric motor functions and food intake. A authors' reply. 49:1363-1364. 2019
- Editorial: rethinking predictors of response to the low FODMAP diet - should we retire fructose and lactose breath-hydrogen testing and concentrate on visceral hypersensitivity?. 45:1281-1282. 2017